Vyant Bio, Inc. Common Stock
VYNT
VYNT was delisted on the 12th of May, 2023.
28 hedge funds and large institutions have $17.3M invested in Vyant Bio, Inc. Common Stock in 2014 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 8 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
18% less funds holding
Funds holding: 34 → 28 (-6)
28% less capital invested
Capital invested by funds: $24M → $17.3M (-$6.68M)
67% less call options, than puts
Call options by funds: $48K | Put options by funds: $147K
75% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
Castleark Management
Chicago,
Illinois
|
+$1.78M |
| 2 |
SIM
SSI Investment Management
Los Angeles,
California
|
+$405K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$236K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$140K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$80.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$2.36M |
| 2 |
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System
Harrisburg,
Pennsylvania
|
-$1.69M |
| 3 |
NC
Northpointe Capital
Bloomfield Hills,
Michigan
|
-$1.43M |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$484K |
| 5 |
PP
PDT Partners
New York
|
-$301K |
VYNT Hedge Fund Activity: Q3 2014 in Review
28 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q3 2014, worth a combined $17.3M — down 28% from $24M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of VYNT and 2 opened new positions — a net loss of 6 holders — while 6 trimmed existing stakes and 10 added.
The largest buyer was Castleark Management, opening a new position worth an estimated $1.78M. The largest seller was Deerfield Management, exiting entirely with an estimated $2.36M sold.
- 28 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q3 2014, down from 34 in Q2 2014.
- Funds reported $17.3M of Vyant Bio, Inc. Common Stock stock for Q3 2014, down 28% quarter-over-quarter.
- 2 funds opened new Vyant Bio, Inc. Common Stock positions in Q3 2014 and 8 closed out, a net change of -6 holders.
- The largest Vyant Bio, Inc. Common Stock buyer in Q3 2014 was Castleark Management, an estimated $1.78M added.
- The largest Vyant Bio, Inc. Common Stock seller in Q3 2014 was Deerfield Management, an estimated $2.36M sold.
Based on aggregated 13F filings for Q3 2014.